Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-31T16:19:26.340Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug Treatment of Anxiety: A Controlled Study of Opipramol and Chlordiazepoxide

Published online by Cambridge University Press:  29 January 2018

H. H. Grosser  and
E. Ryan
H. H. Grosser
Affiliation:
Uffculme Clinic, Birmingham 13; Neuro-Psychiatric University Clinic, Ortenbergstrasse 8, 355 Marburg/Lakn, Germany
E. Ryan
Affiliation:
Uffculme Clinic, Birmingham 13; now St. Finan's Hospital, Killarney, Co. Kerry, Ireland
Get access Rights & Permissions [Opens in a new window]

Extract

Following the introduction of imipramine hydrochloride as the first specific thymoleptic drug, further compounds related to the iminodibenzyl family were developed. One of these was an iminostilbene derivative with a piperazine sidechain: opipramol (Insidon, Geigy), which has the formula 4-[3-(5H-dibenzo[b,f] azepine-5-yl)-propyl]-1-(2-hydroxyethyl)-piperazine-dihydrochloride (Schindler and Blattner, 1961). The nucleus is almost identical to that of imipramine and the sidechain is identical to that of perphenazine. This compound has since been used by a number of Continental and American investigators. They have claimed thymoleptic, neuroleptic and tranquillizing properties for the drug. Some authors found an antidepressive effect inferior to that of imipramine (Schneider and Villa, 1961; Racamier, 1962); others considered it superior to imipramine in that it causes fewer side-effects and helps patients unresponsive to imipramine (Schmitt et al., 1962). Most workers mention a mild sedative effect. Donzallaz (1961) achieved most favourable results treating “psycho-autonomic disturbances”, and Hoff (1962) reported good effects on neurasthenic patients with depressive traits. All these studies were uncontrolled and, on the whole, rather impressionistic. The only blind trial known to us was done by S. R. Splitter (1963), who gave opipramol and placebo on a double-blind basis to 100 medical out-patients suffering from various disorders, with or without psychosomatic symptoms, and also exhibiting some degree of anxiety and depression. Using concomitant drug therapy as required in about half his cases, he observed excellent or good responses of target symptoms including depression, anxiety and psychosomatic complaints, as well as amelioration of any physiologic disorder in 94 per cent. of the opipramol group as against 4 per cent. in the placebo group. However Splitter's material covered a large number of divergent conditions such as adolescent behaviour problems, diabetes and cancer; they were insufficiently matched for diagnosis and apparently not at all for age.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 111 , Issue 471 , February 1965 , pp. 134 - 141
Copyright
Copyright © Royal College of Psychiatrists, 1965 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Azima, H., Arthurs, D., and Silver, A. (1962). “The effects of chlordiazepoxide (Librium) in anxiety states.” Canad. psychiat. Ass. J., 7, 44.Google Scholar
Donzallaz, E. J. (1961). “Expérience clinique d'un nouveau produit à indication psycho-végétative, l'Insidon, en médecine pratique.” Praxis, 50, 1095–1096.Google Scholar
Gore, C. P., and McComisky, J. G. (1961). “A study of the comparative effectiveness of Librium, amylobarbitone and a placebo in the treatment of tension and anxiety states.” Paper read at the Third World Congress of Psychiatry, Montreal, June, 1961.Google Scholar
Hoff, F. E. (1962). “Et nytt psychofarmacum i privat praksis.” T. Norsks Laegeforen, 23, 1575–1577.Google Scholar
Jenner, F. A., Kerry, R. J., and Parkin, D. (1961). “A controlled trial of methaminodiazepoxide (chlordiazepoxide, ‘Librium’) in the treatment of anxiety in neurotic patients.” J. Ment. Sci., 107, 575–582.CrossRefGoogle Scholar
Racamier, P. (1962). “Un nouveau médicament dérivé de l'iminostilbène dans le traitement des états dépressifs.” Presse Méd., 54, 2645–2646.Google Scholar
Scherbel, A. L. (1961). “Preliminary evaluation of chlordiazepoxide.” Amer. Practit., 12, 275.Google Scholar
Schindler, W., and Blattner, H. (1961). “On derivatives of iminodibenzyl, with special reference to iminostilbene.” Helv. chim. Acta., 44, 753.CrossRefGoogle Scholar
Schmitt, W., Meyer, H. H., Quadbeck, G., and Vogt, J. (1962). “Die Pharmakotherapie depressiver Psychosen mit einem neuen Iminostilben Derivativ.” Med. Klin., 57, 49–53.Google Scholar
Schneider, P. B., and Villa, J. L. (1961). “Essai d'un nouveau médicament antidépressif, le G.33040.” Praxis, 50, 1378–1381.Google Scholar
Splitter, S. R. (1963). “Comprehensive treatment of office patients with the aid of a new psychophysiologic agent, opipramol (Ensidon).” Psychosomatics, 4, 283.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.